发明名称 |
Concomitant pharmaceutical agents and use thereof |
摘要 |
A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and
(b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof. |
申请公布号 |
US8754032(B2) |
申请公布日期 |
2014.06.17 |
申请号 |
US200611916356 |
申请日期 |
2006.06.02 |
申请人 |
Mitsubishi Tanabe Pharma Corporation |
发明人 |
Abe Yuji;Anabuki Jun;Akahoshi Fumihiko |
分类号 |
A61K31/133;A61K31/155 |
主分类号 |
A61K31/133 |
代理机构 |
Leydig, Voit & Mayer, Ltd. |
代理人 |
Leydig, Voit & Mayer, Ltd. |
主权项 |
1. A method for treating hyperglycemia, diabetes, an insulin resistant glucose metabolism disorder, an impaired glucose tolerance condition, or an impaired fasting plasma glucose condition in a warm-blooded mammal, which comprises simultaneously or separately administering
(a) 1-50 mg of 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine 2.5 hydrobromide, or a hydrate thereof, and (b) an antidiabetic drug selected from the group consisting of (i) a sulfonylurea agent, (ii) a glitazone, (iii) a biguanide, and (iv) an alpha-glucosidase inhibitor, or a pharmaceutically acceptable salt thereof,to a warm-blooded mammal, thereby treating hyperglycemia, diabetes, an insulin resistant glucose metabolism disorder, an impaired glucose tolerance condition, or an impaired fasting plasma glucose condition in the warm-blooded mammal.
|
地址 |
Osaka JP |